1. Search Result
Search Result
Results for "

Cpd A

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Peptides

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153386

    Anaplastic lymphoma kinase (ALK) Cancer
    CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth .
    CPD-1224
  • HY-147310

    Toll-like Receptor (TLR) Infection
    CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .
    CU-CPD107
  • HY-RS03089

    Small Interfering RNA (siRNA) Others

    CPD Human Pre-designed siRNA Set A contains three designed siRNAs for CPD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CPD Human Pre-designed siRNA Set A
    CPD Human Pre-designed siRNA Set A
  • HY-161606

    PARP Cancer
    PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC50 of < 10 nM .
    PARP-1/2/7-IN-1
  • HY-161607

    PARP Cancer
    PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC50 of < 10 nM .
    PARP7-IN-21
  • HY-144028

    Trk Receptor Cancer
    Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity .
    Pan-Trk-IN-2
  • HY-163533

    VEGFR Inflammation/Immunology
    CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis .
    CPD-002
  • HY-158340

    JAK Cancer
    TYK2 ligand 1 is a TYK2 ligand in the synthesis of PROTAC-based TYK2 degrader (CPD-155, HY-158142) .
    TYK2 ligand 1
  • HY-N7893

    Others Others
    Ebracteolata cpd B is a natural phenol compound found in Euphorbia ebracteolata .
    Ebracteolata cpd B
  • HY-158142

    PROTACs JAK Cancer
    PROTAC TYK2 degrader-1 (CPD-155) is a PROTAC targeting degrader to TYK2 with Dmax >60%. (Srtucture Note: PINK, TYK2 ligand 1 (HY-158340); Blue, VHL ligand Thalidomide (HY-14658); Black, linker)
    PROTAC TYK2 degrader-1
  • HY-134621

    Histone Acetyltransferase Cancer
    P300-IN-1 (cpd205) is a Histone acetylase p300 inhibitor .
    P300-IN-1
  • HY-153441

    TAM Receptor Cancer
    AXL-IN-15 (cpd391) is a potent Axl inhibitor with both Ki and IC50 <1 nM. AXL-IN-15 can be used for research in cancer .
    AXL-IN-15
  • HY-P4523

    Endogenous Metabolite Endocrinology
    FA-Ala-Arg is a dipeptide with furylacryloyl group. FA-Ala-Arg breaks down to produce arginine. While cell-surface Carboxypeptidase-D (CPD) also increases intracellular Arg, which is converted to nitric oxide (NO). FA-Ala-Arg enhances NO production in MCF-7 cells. FA-Ala-Arg also increases the cell survival of prolactin (PRL)-treated cells, PRL regulates CPD mRNA levels in cells .
    FA-Ala-Arg
  • HY-160167

    Btk Inflammation/Immunology
    BTK-IN-30 (compound cpd15) is an inhibitor of Bruton's Tyrosine Kinase (BTK) and mutant BTK with IC50 values of 6.72 and 6.11nM respectively .
    BTK-IN-30
  • HY-163705

    FGFR Cancer
    BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))
    BR-cpd7
  • HY-158009

    Others Cancer
    SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia .
    SGF29-IN-1
  • HY-W471937

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    α1b-AR antagonist 1 (Compound Cpd1) is a selective α1B-AR antagonist. Alpha1b-ar antagonist 1 can be used in the study of cardiovascular and central nervous system diseases .
    α1B-AR antagonist 1
  • HY-143498

    DNA/RNA Synthesis Cancer
    ERCC1-XPF-IN-1 is a potent and high-affinity ERCC1-XPF inhibitor with IC50 value of 0.49 μM. ERCC1-XPF-IN-1 has the capacity to potentiate the cytotoxicity effect of UV radiation and inhibiting DAN repair, by the inhibition of removal of CPDs, and cyclophosphamide toxicity to colorectal cancer cells .
    ERCC1-XPF-IN-1
  • HY-169059

    Ferroptosis Inflammation/Immunology
    Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .
    Ferroptosis-IN-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: